
|Articles|January 10, 2007
Sutent and Nexavar Put Brakes on Renal-Cell Carcinoma
NEW YORK -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.
Advertisement
NEW YORK, Jan. 10 -- Two drugs, Sutent (sunitinib) and Nexavar (sorafenib), slowed progression of advanced renal-cell carcinoma, investigators reported today, but it was not clear whether either agent would extend overall survival significantly.
Sutent more than doubled progression-free survival (P
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Patient Care Online
1
Stroke Prevention Starts in Primary Care, Vascular Neurologist Says
2
Why Prostate Cancer Screening Belongs in Primary Care
3
Probiotic Use Surges as Fiber Intake Stagnates in US Adults, Young Adults
4
The Future of PMOS Care: GLP-1 Therapy and Weight-Loss Caution
5


























































































































